New combo aims to cut transfusions for blood disorder patients
NCT ID NCT07338344
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding low-dose thalidomide to luspatercept can reduce the number of blood transfusions needed by adults with transfusion-dependent β-thalassemia. 78 participants will be randomly assigned to receive either the combination or luspatercept alone for 48 weeks. The main goal is to see if the combo leads to a 50% or greater reduction in transfusion needs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
luspatercept combined with low-dose thalidomide
What this could lead to
If it works, this combination could reduce the need for regular blood transfusions in people with β-thalassemia, improving their quality of life.
What could go wrong
This is a small Phase 2 trial, so results may not apply to everyone. The combination may cause side effects or not work better than luspatercept alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSFUSION-DEPENDENT Β-THALASSEMIA PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Youjiang Medical College for Nationalities
RECRUITINGBaise City, Guangxi, 533000, China
Contact
-
Baise People's Hospital
RECRUITINGBaise City, Guangxi, 533000, China
Contact
-
Liuzhou People's Hospital
RECRUITINGLiuzhou, Guangxi, 545007, China
Contact Phone: •••-•••-••••
-
Liuzhou Workers' Hospital
RECRUITINGLiuzhou, Guangxi, 545007, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Southern Medical University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518100, China
Contact
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNaning, 530000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yulin First People's Hospital
RECRUITINGYulin, Guangxi, 537000, China
Contact
-
Yunnan Provincial First People's Hospital
RECRUITINGKunming, Yunnan, 650100, China
Contact